Articles related to DEVICE/DRUG APPROVALS

Discover how Miebo, supported by phase 3 clinical trials, offers a unique approach to dry eye disease by specifically targeting tear evaporation.

New pharmaceutical interventions are significantly broadening the scope of presbyopia treatment. Discover how these emerging options can enhance your practice and improve patient care.

Stay informed with the FDA’s latest update on temozolomide labeling, which includes new indications and safety guidelines crucial for treating specific brain tumors.

Explore the FDA-approved Tyruko, a biosimilar to Tysabri, which has shown comparable safety and efficacy in phase 3 clinical trials for treating relapsing forms of MS.

Discover the latest advancements in ADHD therapies that promise greater efficacy and fewer side effects—options that can revolutionize personalized treatment plans.

Discover how Elrexfio’s conditional FDA approval could redefine the treatment landscape for patients with difficult-to-treat multiple myeloma. Dive into the promising clinical trial results and understand its potential impact on your practice.